FierceBiotech1d
Gilead roars into JPM25, inking $1.7B inflammation deal with Leo Pharma
Gilead Sciences continues its divergence out of its original infectious disease beginnings and into cancer and now, more ...
Gilead in pact for anti-inflammatory drugs in a deal worth up to $1.7B
Gilead Sciences (NASDAQ:GILD) and Danish pharmaceutical company LEO Pharma on Saturday announced an agreement worth up to ...
BioWorld16d
STAT6 stat sig? Kaken, J&J $1.2B-plus deal adds oomph to space
Kaken Pharmaceutical Co. Ltd.’s license agreement with Johnson & Johnson (J&J) for signal transducer and activator of ...
Business Wire24d
DeepCure Unveils STAT6 Inhibitor Program with Novel Oral Small Molecules Targeting Type 2 Inflammation
These next-generation STAT6 inhibitors demonstrate excellent oral bioavailability, cell permeability, and metabolic stability, and do not target STAT6 for degradation. DeepCure expects to select a ...
Hosted on MSN16d
JNJ Inks Licensing Deal With Kaken for Eczema Candidate KP-723
Johnson & Johnson JNJ announced entering into an exclusive global licensing agreement with Kaken Pharmaceutical to develop, ...
Johnson & Johnson licensing STAT6 program from Kaken Pharmaceutical
Johnson & Johnson announced that it has entered into an exclusive licensing agreement for the global development, manufacturing and ...
Yahoo Finance17d
Leerink sees positive readthrough for Kymera Therapeutics from J&J-Kaken deal
Kymera has recently started a Phase 1 for STAT6 degrader KT-621, while JNJ announced an in-licensing deal with Japan-based Kaken Pharmaceutical for small molecule STAT6 program KP-723, and while ...